PIPAC and minimally invasive surgery for high-risk stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a special chemotherapy sprayed into the abdomen (PIPAC) and a minimally invasive surgery to remove the stomach in people with high-risk stomach cancer. The goal is to see if this approach can improve outcomes for patients whose cancer has grown into the stomach wall or spread to abdominal fluid but not to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stomach cancer or cancer at the junction of the stomach and esophagus (Siewert type III).
- Your cancer has not spread to distant organs (like the liver or lungs), but may have spread to the fluid in your abdomen (which cleared with chemotherapy).
- You are well enough to do daily activities without help (ECOG 0-1).
- You are willing to have a robotic or laparoscopic surgery to remove your stomach and nearby lymph nodes (D2 gastrectomy).
- You have normal kidney, heart, liver, and blood counts, and are not allergic to the chemotherapy drugs used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
This trial tests if a special type of chemotherapy delivered as a mist during surgery (PIPAC) can help prevent the spread of stomach cancer. It is for people with advanced but not yet metastatic stomach cancer who have not had prior treatment.
This trial tests a minimally invasive surgery for stomach cancer that has spread to lymph nodes near the main blood vessels (para-aortic area). The surgery is done after a combination of chemotherapy and immunotherapy to shrink the tumor. It aims to see if this approach is safe and effective.
This trial studies chemotherapy given before surgery for advanced stomach (gastric) cancer, including treatment when cancer may be on the stomach lining (peritoneum). It may help shrink tumors and improve outcomes for people who meet specific marker and staging requirements.
This trial looks at a way to give chemotherapy into the abdomen (through a small tube during laparoscopy) for certain stomach cancers. It aims to see whether this approach improves cancer control and surgical outcomes for people whose tumors can potentially be removed.
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.